Senior Care Pharmacist最新文献

{"title":"Predictors of Use of Individual Insulin and GLP-1 RA Products Versus Fixed Ratio Insulin/GLP-1 RA Combinations in Medicare Beneficiaries.","authors":"Anthony F Jeter, Brittany L Melton, Bradley J Newell","doi":"10.4140/TCP.n.2025.97","DOIUrl":"10.4140/TCP.n.2025.97","url":null,"abstract":"<p><p><b>Background:</b> In 2022, federal law capped insulin product costs at $35 per month for Medicare prescription drug plan recipients. However, this law did not address the high costs of other antihyperglycemic medications, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), with an average copay of $120 per month. Under the law, fixed-ratio insulin/GLP-1RA combination products are classified as \"insulin products,\" making these effective medications more accessible to patients who might otherwise be unable to afford them. Patients may not be aware of the potential financial benefits of combination products, highlighting the need to identify those using them to better educate both patients and providers. <b>Objectives:</b> The primary objective was to identify predictors of use for the insulin/GLP-1RA combinations. The secondary objective was to determine if there was a difference in medication cost to patients between individual and combination product users and determine cost savings potential of switching. <b>Design:</b> This was a retrospective, observational cohort analysis. <b>Setting:</b> Prescription fill data were examined for antihyperglycemic medications filled between January 1, 2022, and December 31, 2022. Prescriptions were filled within one regional division of a large community-based pharmacy chain, encompassing 71 pharmacies within Kansas, Nebraska, and Missouri. <b>Methods:</b> This retrospective observational cohort analysis examined prescription fill data for antihyperglycemic medications for the calendar year 2022 across one regional division of a large community-based pharmacy chain. Included patients 65 years of age or older with a Medicare prescription drug plan, using any basal insulin and any GLP-1RA, including combinations, as well as metformin, with ≥ 80% proportion of days covered. Demographics, usage predictors, and cost differences were compared between patients using individual products and those using insulin/GLP-1RA combination products. <b>Results:</b> A total of 138 patients were analyzed. The use of insulin/GLP-1RA combination products was associated with increased likelihood of using sodium-glucose cotransporter-2 inhibitors (<i>P</i> = 0.022). Median annual out-of-pocket spending was significantly different between groups (<i>P</i> < 0.001), with most combination users paying more than $1,000 less per year than individual product users. <b>Conclusion:</b> Insulin/GLP-1RA combination products represent a cost-effective alternative to individual antidiabetic pharmacotherapy agents.</p>","PeriodicalId":41635,"journal":{"name":"Senior Care Pharmacist","volume":"40 2","pages":"97-104"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Recalibration of Power: Republicans Take Control of the Senate and Key Health Care Committees.","authors":"Leigh Davitian","doi":"10.4140/TCP.n.2025.105","DOIUrl":"10.4140/TCP.n.2025.105","url":null,"abstract":"","PeriodicalId":41635,"journal":{"name":"Senior Care Pharmacist","volume":"40 2","pages":"105-108"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insulin Pen Administration Efficacy and Safety in an Older Patient.","authors":"Dylan K Montgomery, Tiffany R Shin, Bradley J Newell","doi":"10.4140/TCP.n.2025.64","DOIUrl":"10.4140/TCP.n.2025.64","url":null,"abstract":"<p><p><b>Objective</b> To describe a successful pharmacist-led intervention to effectively and safely provide education and pharmacotherapy management for an older patient with uncontrolled type 2 diabetes mellitus (T2DM) who failed to remove the needle shield on insulin pens for injection. <b>Setting:</b> Family medicine residency clinic. <b>Practice Description:</b> The clinic, part of a major urban health system, consists of 27 medical residents, 15 attending physicians, and 1 ambulatory care pharmacist managing chronic diseases collaboratively. It primarily serves low-income patients in a Midwest city. <b>Practice Innovation:</b> A 93-year-old White female with T2DM, receiving insulin therapy, was referred to the ambulatory care pharmacist by her physician for diabetes management. The patient had been hospitalized recently for hyperosmolar hyperglycemic state with a hemoglobin A1c of 15.9%. The pharmacist identified a failure to remove the needle shield on the insulin pen resulting in ineffective insulin administration, which caused persistent hyperglycemia and subsequent hospitalizations. This also posed a safety concern for severe hypoglycemia if proper administration resumed without adjusting the inflated dosing. The pharmacist used demonstration devices and the teach-back method to provide education and implement pharmacotherapy adjustments, resulting in effective and safe insulin administration. <b>Main Outcome Measurements:</b> Change in diabetes medication regimen, home blood glucose readings including continuous glucose monitor data, hemoglobin A1c results, frequency of hypoglycemic episodes, and number of hospitalizations for T2DM. <b>Results:</b> Over seven months, dose adjustments to basal insulin, combined with proper administration technique and the addition of empagliflozin, resulted in a hemoglobin A1c below 7%, with no severe hypoglycemia or diabetes-related hospitalizations. <b>Conclusion:</b> Medication errors, including insulin administration errors, highlight the need for thorough education in insulin therapy management. Education and monitoring empower older patients to self-manage diabetes safely and effectively, aligning with guidelines. Further research is required to identify optimal strategies for educating older patients on self-managing T2DM with insulin therapy.</p>","PeriodicalId":41635,"journal":{"name":"Senior Care Pharmacist","volume":"40 2","pages":"64-71"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Dry Mouth.","authors":"Renee L Hayslett, Leisa L Marshall","doi":"10.4140/TCP.n.2025.55","DOIUrl":"10.4140/TCP.n.2025.55","url":null,"abstract":"<p><p><b>Background:</b> Dry mouth, or xerostomia, is a common complaint among older people. Dry mouth can result in a variety of dental complications, oral discomfort, difficulty swallowing and eating, and decreased taste sensation, all of which can adversely affect quality of life. <b>Objective:</b> To provide an overview of the definition, diagnosis, causes, potential complications, and treatment strategies for dry mouth. <b>Data Sources:</b> PubMed, Proquest, Cochrane Library, drug prescribing information, drug information databases, and manufacturers' websites were used. Search terms were \"xerostomia,\" \"dry mouth,\" \"hyposalivation,\" \"causes,\" \"treatment,\" and \"pharmacology.\" The resources identified included clinical practice guidelines, review articles, and original research articles. <b>Data Synthesis:</b> The literature described the causes and treatment strategies for managing xerostomia, including concerns for older adults, and pharmacists' involvement for providing care. <b>Discussion:</b> The most common cause of dry mouth in the general population and in older adults is medication use. Individual medications may cause dry mouth, primarily through anticholinergic side effects. Polypharmacy is also a cause. Other causes are dehydration, alcohol and caffeine intake, and systemic diseases such as Sjögren's disease. If not addressed, individuals experiencing chronic dry mouth are at increased risk for various oral conditions such as dental caries, periodontal disease, and infections. Interventions such as good oral hygiene methods, using saliva substitutes containing xylitol and prescription cholinergic agonists, if appropriate, can reduce symptoms and complications. <b>Conclusion:</b> Pharmacists can play an important role in managing dry mouth by conducting medication reviews, providing patient education for oral health practices, and recommending treatment strategies.</p>","PeriodicalId":41635,"journal":{"name":"Senior Care Pharmacist","volume":"40 2","pages":"55-63"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination Inhaled Corticosteroid and Short-acting Beta2 Agonist (ICS-SABA) Use for Older Adults With Asthma.","authors":"Jaycie Truong, Kimberly A B Cauthon","doi":"10.4140/TCP.n.2025.3","DOIUrl":"https://doi.org/10.4140/TCP.n.2025.3","url":null,"abstract":"<p><p>The first combination inhaled corticosteroid and short-acting beta₂ agonist (ICS-SABA) was approved by the Food and Drug Administration (FDA) in 2023 for as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma exacerbations in patients 18 years of age and older. The recently approved product contains an ICS-albuterol combination. The 2024 Global Initiative for Asthma (GINA) guidelines recommend as-needed ICS-formoterol as the preferred asthma reliever therapy; however, a GINA alternative recommendation is the use of ICS whenever an as-needed (SABA) is used. There is no difference in as-needed asthma treatment recommended by the GINA guidelines in older adults, and there has been minimal study in older adults. Because of limited guidance on the use of the ICS-SABA reliever inhaler in older adults, the purpose of this review is to evaluate the DENALI and MANDALA studies and the potential role of ICS-SABA in older adults. The mean ages in both studies were 50 years. The MANDALA primary outcome result was a statistically significant lower risk of severe exacerbations in the ICS-SABA reliever group compared with the as-needed albuterol (ALB) group at 24 weeks. In the MANDALA older adults subgroup analysis, there was not a statistically significant difference in the ICS-SABA reliever group compared with the as-needed ALB-alone group but the results favored ICS-SABA. The DENALI primary outcome results were a greater change from baseline in forced expiratory volume in the first second (FEV1) area under the curve averaged over 12 weeks with albuterol/budesonide (ALB-BUD) 180/160 ug compared with budesonide alone and placebo and a greater change from baseline in trough FEV1 with ALB-BUD 180/160 ug and 180/80 ug than ALB-alone and placebo. Because of minimal adverse effects in both trials and the benefits in preventing asthma exacerbations reported in the MANDALA trial, it is important to assess and recommend that older adults with asthma receive inhaled corticosteroid with their reliever asthma inhaler.</p>","PeriodicalId":41635,"journal":{"name":"Senior Care Pharmacist","volume":"40 1","pages":"3-9"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibiotic Length of Therapy: Is Shorter Better in Older Adults?","authors":"Alice N Hemenway, Caitlyn Patton, Elias B Chahine","doi":"10.4140/TCP.n.2025.18","DOIUrl":"10.4140/TCP.n.2025.18","url":null,"abstract":"<p><p><b>Background</b> Antibiotic lengths of therapy (LOT) vary widely, based on infection type, antibiotic regimen, and patient characteristics. Longer LOT are associated with increased risk of antibiotic resistance, adverse effects, and health care costs. There are increasing data supporting shorter LOT for many infections based on randomized, controlled trials (RCTs). <b>Objective</b> To evaluate RCTs supporting shorter antibiotic LOT for common infections, with an emphasis on applying the data to older adults. <b>Data Sources</b> A list of RCTs that evaluated shorter LOT for common infections was first gathered from the website of Brad Spellberg, MD, at <ext-link ext-link-type=\"uri\" xlink:href=\"https://www.bradspellberg.com/shorter-is-better\">https://www.bradspellberg.com/shorter-is-better</ext-link>. The list was then verified through a PubMed search using the terms for each infection and LOT. <b>Data Synthesis</b> Of the 28 identified RCTs, 27 supported shorter antibiotic LOT. These trials were categorized by disease states: complicated urinary tract infections including pyelonephritis (n = 9), community-acquired pneumonia (n = 6), hospital-acquired pneumonia/ ventilator-associated pneumonia (n = 3), skin and soft tissue infections (n = 4), complicated intra-abdominal infections (n = 2), and gram-negative bacteremia (n = 3). The single incongruent trial was conducted on male patients with complicated urinary tract infections, and the results could be explained by a lower than usual dose of antibiotic utilized in the study. <b>Discussion</b> Many RCTs have demonstrated the safety and efficacy of shorter antibiotic LOT for the disease states included in this review. Several of these trials enrolled older adults. <b>Conclusion</b> There are sufficient data to support using shorter antibiotic LOT in older patients. Implementing this strategy can help pharmacists and other health care professionals optimize antibiotic use in older adults.</p>","PeriodicalId":41635,"journal":{"name":"Senior Care Pharmacist","volume":"40 1","pages":"18-31"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complicated Overactive Bladder Management.","authors":"Kaylee Mehlman, Victoria Nalls, Douglas Wessel","doi":"10.4140/TCP.n.2025.10","DOIUrl":"10.4140/TCP.n.2025.10","url":null,"abstract":"<p><p>These case studies review the treatment of patients with overactive bladder (OAB), a chronic condition presenting with urinary urgency, often occurring with frequency and nocturia, which may or may not be associated with urinary incontinence. Patients with OAB can have multiple clinical factors to consider when selecting the optimal therapy, and this treatment series provides examples of approaches to balance treatment selection with other comorbidities and patient expectations.</p>","PeriodicalId":41635,"journal":{"name":"Senior Care Pharmacist","volume":"40 1","pages":"10-17"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Slow Crawl to Making a President's Cabinet: Vetting, Nominating, and Confirming.","authors":"Leigh Davitian","doi":"10.4140/TCP.n.2025.50","DOIUrl":"https://doi.org/10.4140/TCP.n.2025.50","url":null,"abstract":"<p><p>This article will serve as a quick historical summary of the notorious process of vetting, nominating, and confirming Cabinet members, with a particular emphasis on how it is playing out for President-elect Trump.</p>","PeriodicalId":41635,"journal":{"name":"Senior Care Pharmacist","volume":"40 1","pages":"50-53"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary Supplement Safety in Older Adults: A Review of Published Case Reports.","authors":"Alex Shahverdian, Mahtab Jafari","doi":"10.4140/TCP.n.2025.32","DOIUrl":"10.4140/TCP.n.2025.32","url":null,"abstract":"<p><p><b>Objective:</b> This review summarizes recent case reports where the consumption of dietary supplements by older adults may have caused an adverse event. <b>Data Sources:</b> In December 2023, PubMed was surveyed for case reports published from 2000 onwards, using two medical subject heading (MeSH) terms, \"aged\" and \"dietary supplements,\" where the latter was combined with the MeSH subheadings \"adverse effects,\" \"poisoning,\" or \"toxicity.\" Major clinical trials for dietary supplements were identified at <ext-link ext-link-type=\"uri\" xlink:href=\"https://ClinicalTrials.gov\">ClinicalTrials.gov</ext-link>, an online database of clinical research studies, or in PubMed, and screened for information on adverse effects. <b>Data Synthesis:</b> The described search strategy yielded 820 publications, including 122 case reports, which were then manually screened for relevant and informative case reports involving dietary supplements and people 65 years of age or older. Consequently, 41 publications were selected describing 46 individual case reports. Etiologies of adverse events included interactions of dietary supplements with prescribed medication, ingestion of higher-than-intended or instructed supplement doses, intake of the same supplement from multiple sources, and supplement contamination. Prominent adverse events encompassed hypercalcemia (vitamin D), thyroid test interference (vitamin B7), neuropathy (vitamin B6), oxalate nephropathy (vitamin C), and interactions with warfarin therapy (vitamins E and K, and omega-3 fatty acids). <b>Conclusion:</b> Health care practitioners are advised to consider dietary supplements as contributors to adverse clinical symptom presentations, while patients are encouraged to provide current records of their prescribed medications and dietary supplements to their health care providers. This is particularly important for older adults where both medication intake and supplement consumption are high.</p>","PeriodicalId":41635,"journal":{"name":"Senior Care Pharmacist","volume":"40 1","pages":"32-49"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endings and Beginnings.","authors":"Chris Alderman","doi":"10.4140/TCP.n.2025.1","DOIUrl":"https://doi.org/10.4140/TCP.n.2025.1","url":null,"abstract":"<p><p>Editor Emeritus Chris Alderman reflects on his past five years in his role with The Senior Care Pharmacist. This editorial is his farewell address to the readers as new editors in chief take the helm.</p>","PeriodicalId":41635,"journal":{"name":"Senior Care Pharmacist","volume":"40 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}